Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research
Sub-Industry: Biotechnology
Symbol: NASDAQ:IMMU
CUSIP: 45290710
Web: www.immunomedics.com

Capitalization:

Market Cap: $1.28 billion
Outstanding Shares: 111,279,000

Average Prices:

50 Day Moving Avg: $10.09
200 Day Moving Avg: $7.94
52 Week Range: $2.02 - $12.96

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -44.12
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $3.09 million
Price / Sales: 413.06
Book Value: ($0.53) per share
Price / Book: -21.64

Profitability:

EBIDTA: ($71,330,000.00)
Net Margins: -4,956.52%
Return on Assets: -109.37%

Debt:

Debt-to-Equity Ratio: -1.65%
Current Ratio: 1.29%
Quick Ratio: 1.28%

Misc:

Average Volume: 2.57 million shs.
Beta: 1.65
Short Ratio: 19.33

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.13. The firm had revenue of $0.64 million for the quarter, compared to analysts' expectations of $0.75 million. Immunomedics's revenue for the quarter was down 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 analysts have issued 12-month price objectives for Immunomedics' shares. Their predictions range from $14.00 to $15.00. On average, they expect Immunomedics' share price to reach $14.50 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in August. As of August 31st, there was short interest totalling 34,287,202 shares, an increase of 0.6% from the August 15th total of 34,074,923 shares. Based on an average daily volume of 4,662,516 shares, the days-to-cover ratio is currently 7.4 days. Approximately 34.4% of the shares of the company are short sold.

Who are some of Immunomedics' key competitors?

Some companies that are related to Immunomedics include Blueprint Medicines Corporation (BPMC), Ironwood Pharmaceuticals (IRWD), Sage Therapeutics (SAGE), Intrexon Corporation (XON), Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA) and BeyondSpring (BYSI).

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

Jason M. Aryeh, Chairman of the Board
Cynthia L. Sullivan, President, Chief Executive Officer, Director
Michael R. Garone, Chief Financial Officer, Vice President - Finance
David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
Geoffrey F. Cox Ph.D., Independent Director
Robert Forrester, Independent Director
Brian A. Markison, Lead Independent Director
Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Lord Abbett & CO. LLC, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC and EAM Investors LLC. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $11.47.

MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		145 (Vote Outperform)
Underperform Votes:		115 (Vote Underperform)
Total Votes:		260

MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	3 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$14.50 (26.42% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/19/2017	Jefferies Group LLC	Boost Price Target	Buy	$11.00 -> $14.00	High
7/24/2017	Cowen and Company	Reiterated Rating	Outperform	$15.00	Low
5/5/2017	Wells Fargo & Co	Upgrade	Market Perform -> Outperform		High

(Data available from 9/25/2015 forward)

Earnings History for Immunomedics (NASDAQ:IMMU)

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Earnings History by Quarter for Immunomedics (NASDAQ IMMU)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/16/2017	Q4 2017	($0.12)	($0.25)	$0.75 million	$0.64 million	View	N/A
2/9/2017	Q2 2017	($0.13)	($0.16)	$0.70 million	$0.38 million	View	Listen
11/2/2016	Q117	($0.14)	($0.17)	$0.70 million	$0.74 million	View	N/A
8/17/2016	Q416	($0.11)	($0.17)	$0.90 million	$0.93 million	View	Listen
5/4/2016	Q3	($0.13)	($0.15)	$0.70 million	$0.90 million	View	N/A
2/3/2016	Q216	($0.14)	($0.15)	$1.40 million	$0.67 million	View	N/A
11/4/2015	Q116	($0.14)	($0.16)	$1.23 million	$0.73 million	View	N/A
8/19/2015	Q415	($0.13)	($0.13)	$1.13 million	$2.40 million	View	Listen
5/6/2015	Q3 2015	($0.13)	($0.13)	$1.07 million	$1.18 million	View	N/A
2/4/2015	Q215	($0.13)	($0.12)	$1.73 million	$1.00 million	View	N/A
11/5/2014	Q1 2015	($0.12)	($0.13)	$1.18 million	$1.07 million	View	N/A
8/25/2014	Q414	($0.13)	($0.13)	$1.20 million	$1.20 million	View	N/A
5/7/2014	Q3 2014	($0.12)	$0.02	$1.13 million	$1.15 million	View	N/A
2/10/2014	Q214	($0.10)	($0.10)	$1.20 million	$1.20 million	View	N/A
8/22/2013	Q4 2013	($0.12)	($0.09)	$0.81 million	$1.40 million	View	N/A
5/8/2013	Q3 2013	($0.10)	$0.11	$0.97 million	$1.70 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Immunomedics (NASDAQ:IMMU)

2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.12)	($0.12)	($0.12)
Q2 2017	1	($0.15)	($0.15)	($0.15)
Q3 2017	1	($0.15)	($0.15)	($0.15)
Q4 2017	1	($0.11)	($0.11)	($0.11)
Q1 2018	1	($0.11)	($0.11)	($0.11)
Q2 2018	1	($0.12)	($0.12)	($0.12)
Q3 2018	1	($0.14)	($0.14)	($0.14)
Q4 2018	1	($0.19)	($0.19)	($0.19)

(Data provided by Zacks Investment Research)

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 77.99%

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/1/2017	David M. Goldenberg	Insider	Sell	20,000	$12.64	$252,800.00
8/28/2017	Cynthia L. Goldenberg	Director	Sell	40,000	$10.72	$428,800.00
8/23/2017	Cynthia L. Goldenberg	Director	Sell	40,000	$9.24	$369,600.00
8/24/2016	Don C Stark	Director	Sell	9,900	$2.97	$29,403.00
8/23/2016	Mary E Paetzold	Director	Sell	15,000	$2.98	$44,700.00
6/13/2016	Cynthia L Goldenberg	CEO	Sell	371,990	$3.03	$1,127,129.70
6/8/2016	Cynthia L Goldenberg	CEO	Sell	41,441	$3.62	$150,016.42
6/8/2016	David M Goldenberg	Chairman	Sell	353,010	$3.88	$1,369,678.80
6/7/2016	Cynthia L Goldenberg	CEO	Sell	4,600	$4.01	$18,446.00
6/7/2016	David M Goldenberg	Chairman	Sell	12,300	$3.98	$48,954.00
6/6/2016	Cynthia L Goldenberg	CEO	Sell	63,959	$4.09	$261,592.31
6/6/2016	David M Goldenberg	Chairman	Sell	110,322	$4.09	$451,216.98
6/15/2015	David M Goldenberg	Chairman	Sell	210,991	$4.08	$860,843.28
6/12/2015	Brian A Markison	Director	Sell	5,564	$4.22	$23,480.08
6/12/2015	David M Goldenberg	Chairman	Sell	359,653	$4.32	$1,553,700.96
6/9/2015	Mary E Paetzold	Director	Sell	4,677	$4.60	$21,514.20
6/5/2015	Don C Stark	Director	Sell	5,732	$4.14	$23,730.48
12/11/2014	Mary E Paetzold	Director	Sell	10,000	$4.71	$47,100.00
12/9/2014	Don C Stark	Director	Sell	5,500	$4.51	$24,805.00
9/13/2013	Don Stark	Director	Sell	10,000	$6.08	$60,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Immunomedics (NASDAQ:IMMU) Latest Headlines for Immunomedics (NASDAQ:IMMU)

Source:

Date	Headline
	Immunomedics, Inc. (IMMU) Given New $14.00 Price Target at Jefferies Group LLC www.americanbankingnews.com - September 24 at 1:00 PM
	Form 8-K IMMUNOMEDICS INC For: Sep 19 - StreetInsider.com www.streetinsider.com - September 22 at 7:02 PM
	Jefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU) www.americanbankingnews.com - September 21 at 11:20 AM
	Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock finance.yahoo.com - September 16 at 1:40 AM
	Immunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow seekingalpha.com - September 14 at 6:28 AM
	Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - September 13 at 2:53 PM
	BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i www.reuters.com - September 12 at 1:39 AM
	Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer finance.yahoo.com - September 12 at 1:39 AM
	Immunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - StreetInsider.com www.streetinsider.com - September 11 at 8:36 PM
	Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - Nasdaq www.nasdaq.com - September 11 at 8:36 PM
	Immunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 Shares www.americanbankingnews.com - September 5 at 10:26 PM
	IMMU Crosses Above Average Analyst Target - Nasdaq www.nasdaq.com - September 1 at 8:13 PM
	Immunomedics to Participate in Upcoming Investor Conferences finance.yahoo.com - August 31 at 6:10 AM
	Immunomedics Stock Breaks Out, Consolidation Likely www.investopedia.com - August 30 at 2:08 AM
	Immunomedics, Inc. (IMMU) Director Sells $428,800.00 in Stock www.americanbankingnews.com - August 28 at 10:22 PM
	Immunomedics, Inc. (IMMU) Upgraded to Buy by BidaskClub www.americanbankingnews.com - August 28 at 8:44 PM
	ETFs with exposure to Immunomedics, Inc. : August 28, 2017 finance.yahoo.com - August 28 at 7:28 PM
	Here's Why Immunomedics Rose as Much as 14.2% Today www.fool.com - August 28 at 4:58 PM
	Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher feeds.benzinga.com - August 28 at 12:52 PM
	Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017 finance.yahoo.com - August 25 at 7:05 AM
	Mid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results feeds.benzinga.com - August 24 at 3:10 PM
	Form 4 IMMUNOMEDICS INC For: Aug 21 Filed by: GOLDENBERG DAVID M www.streetinsider.com - August 24 at 7:58 AM
	Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017 finance.yahoo.com - August 24 at 7:58 AM
	Immunomedics, Inc. (IMMU) Director Cynthia L. Goldenberg Sells 40,000 Shares www.americanbankingnews.com - August 24 at 4:20 AM
	BRIEF-Immunomedics announces publication of cancer drug data - Reuters www.reuters.com - August 22 at 12:05 AM
	Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology globenewswire.com - August 21 at 8:51 AM
	Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer finance.yahoo.com - August 21 at 8:51 AM
	Immunomedics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.10) Per Share (IMMU) www.americanbankingnews.com - August 21 at 6:22 AM
	Immunomedics, Inc. (IMMU) Given Consensus Rating of "Buy" by Analysts www.americanbankingnews.com - August 19 at 12:52 PM
	FY2022 EPS Estimates for Immunomedics, Inc. Cut by Analyst (IMMU) www.americanbankingnews.com - August 18 at 2:28 PM
	Immunomedics, Inc. (IMMU) PT Set at $11.00 by Jefferies Group LLC www.americanbankingnews.com - August 18 at 11:22 AM
	Immunomedics, Inc. (IMMU) Releases Earnings Results, Misses Expectations By $0.13 EPS www.americanbankingnews.com - August 17 at 9:20 AM
	BRIEF-Immunomedics reports Q4 loss per share $0.48 www.reuters.com - August 17 at 5:54 AM
	Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT finance.yahoo.com - August 17 at 5:54 AM
	Immunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - August 17 at 12:52 AM
	Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017 finance.yahoo.com - August 17 at 12:52 AM
	After-Hours Earnings Report for August 16, 2017 : CSCO, NTAP, LB, VIPS, CACI, BGG, SPTN, IMMU, GPRK, PBIO - Nasdaq www.nasdaq.com - August 16 at 7:49 PM
	Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission ... - GlobeNewswire (press release) globenewswire.com - August 16 at 7:49 PM
	Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline finance.yahoo.com - August 16 at 7:49 PM
	Immunomedics reports 4Q loss finance.yahoo.com - August 16 at 7:49 PM
	Zacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold www.americanbankingnews.com - August 11 at 12:28 AM
	Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results finance.yahoo.com - August 7 at 7:15 PM
	Immunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - August 4 at 11:52 PM
	BRIEF-Immunomedics, Covance enter into master services agreement www.reuters.com - August 4 at 8:07 PM
	Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 finance.yahoo.com - August 3 at 7:57 PM
	Immunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - July 25 at 3:07 PM
	Cowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU) www.americanbankingnews.com - July 24 at 4:10 PM
	Immunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - July 18 at 12:56 AM
	FY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group www.americanbankingnews.com - July 17 at 11:11 AM
	Jefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU) www.americanbankingnews.com - July 15 at 4:12 PM